Targeted next‐generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance

HER2‐positive breast cancers are a heterogeneous group of tumors, which share amplification and overexpression of HER2. In routine diagnostics, the HER2 (ERBB2) status is currently assessed by immunohistochemistry (IHC) and in situ hybridization (ISH). Data on targeted next‐generation sequencing (NGS) approaches that could be used to determine the HER2 status are sparse. Employing two breast cancer‐related gene panels, we performed targeted NGS of 41 FFPE breast cancers for which full pathological work‐up including ISH and IHC results was available. Selected cases were analyzed by qPCR. Of the 41 cases, the HER2 status of the 4 HER2‐positive and 6 HER2‐negative tumors was independently detected by our NGS approach achieving a concordance rate of 100%. The remaining 31 cases were equivocal HER2 cases by IHC of which 5 showed amplification of HER2 by ISH. Our NGS approach classified all non‐amplified cases correctly as HER2 negative and corroborated all but one of the 5 cases with amplified HER2 as detected by ISH. For the overall cohort, concordance between the gold standard and NGS was 97.6% (sensitivity 88.9% and specificity 100%). Additionally, we observed mutations in PIK3CA (44%), HER2 (8%), and CDH1 (6%) among others. Amplifications were found in CCND1 (12%), followed by MYC (10%) and EGFR (2%) and deletions in CDKN2A (10%), MAP2K4 and PIK3R1 (2% each). We here show that targeted NGS data can be used to interrogate the HER2 status with high specificity and high concordance with gold standard methods. Moreover, this approach identifies additional genetic events that may be clinically exploitable. © 2016 Wiley Periodicals, Inc.

[1]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.

[2]  R. Bernards,et al.  PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Mingming Jia,et al.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..

[4]  C R King,et al.  Amplification of a novel v-erbB-related gene in a human mammary carcinoma. , 1985, Science.

[5]  Robert B. Jenkins,et al.  MYC Gene Amplification is Often Acquired in Lethal Distant Breast Cancer Metastases of Unamplified Primary Tumors , 2011, Modern Pathology.

[6]  M. Untch,et al.  Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany , 2017, Modern Pathology.

[7]  M. J. van de Vijver,et al.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. , 1988, The New England journal of medicine.

[8]  L. Garrison,et al.  The Lifetime Economic Burden of Inaccurate HER2 Testing: Estimating the Costs of False-Positive and False-Negative HER2 Test Results in US Patients with Early-Stage Breast Cancer. , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[9]  Peter A Kaufman,et al.  HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J. Infante,et al.  Targeting CDK4/6 in patients with cancer. , 2016, Cancer treatment reviews.

[12]  J. Haerting,et al.  Gene-expression signatures in breast cancer. , 2003, The New England journal of medicine.

[13]  F. Sanschagrin,et al.  Advantages and disadvantages of technologies for HER2 testing in breast cancer specimens. , 2015, American journal of clinical pathology.

[14]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[15]  Alain Viari,et al.  A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers , 2016, Nature Communications.

[16]  Volker Endris,et al.  Molecular diagnostic profiling of lung cancer specimens with a semiconductor-based massive parallel sequencing approach: feasibility, costs, and performance compared with conventional sequencing. , 2013, The Journal of molecular diagnostics : JMD.

[17]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[18]  Philippe Bédard,et al.  Clinical application of high-throughput genomic technologies for treatment selection in breast cancer , 2013, Breast Cancer Research.

[19]  M. Ellis,et al.  HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

[20]  Eunyoung Kang,et al.  Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance , 2012, Modern Pathology.

[21]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.

[22]  M. Dowsett,et al.  Standardization of HER2 testing: results of an international proficiency-testing ring study , 2007, Modern Pathology.

[23]  Carsten Denkert,et al.  Ioncopy: a novel method for calling copy number alterations in amplicon sequencing data including significance assessment , 2016, Oncotarget.

[24]  A. Warth,et al.  Quantitative analysis of diagnostic guidelines for HER2-status assessment. , 2012, The Journal of molecular diagnostics : JMD.

[25]  Carsten Denkert,et al.  Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences , 2014, Oncotarget.

[26]  W. Gullick,et al.  OVEREXPRESSION OF THE c-erbB-2 ONCOPROTEIN IN HUMAN BREAST CARCINOMAS: IMMUNOHISTOLOGICAL ASSESSMENT CORRELATES WITH GENE AMPLIFICATION , 1987, The Lancet.

[27]  Carsten Denkert,et al.  PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[29]  S. Bersani,et al.  Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria. , 2009, American journal of clinical pathology.

[30]  S. Goel,et al.  Deciphering the role of phosphatidylinositol 3-kinase mutations in human epidermal growth factor receptor 2-positive breast cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  A. Citri,et al.  EGF–ERBB signalling: towards the systems level , 2006, Nature Reviews Molecular Cell Biology.

[32]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[33]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[34]  Marc E. Lenburg,et al.  MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition , 2012, The Journal of experimental medicine.

[35]  P. Klein,et al.  Concordance between central and local laboratory HER2 testing from a community-based clinical study. , 2006, Clinical breast cancer.

[36]  J. Elam,et al.  Rescue breathing: a modification. , 1959, Lancet.

[37]  Peter A Kaufman,et al.  Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer , 2014, Cancer.

[38]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.